-
Posted by
Two Blokes Jun 25 -
Filed in
Stock
-
4 views
Shares of Arcutis Biotherapeutics have fallen by 5% since my March update. Zoryve's 4th approval in scalp & body psoriasis should further boost sales and contribute to the "portfolio effect". IP developments suggest the company's protection for Zoryve, though related to formulation instead of composition of matter, is stronger than originally thought.
